Filana Therapeutics, Inc. Derivative Liability, Current
Filana Therapeutics, Inc. (FLNA) had Derivative Liability, Current of $65.37 million as of 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2024-05-10
- 2024-03-31: Derivative Liability, Current $65.37M.
- 2023-12-31: Derivative Liability, Current $0.00.
| Period end | Derivative Liability, Current |
|---|---|
| 2024-03-31 | $65.37M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $0.00 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |